Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.14
-5.7%
$2.07
$1.63
$3.26
$13.17M0.8540,117 shs51,377 shs
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$1.10
-2.7%
$1.29
$0.64
$2.92
$46.01M-0.7529,800 shs162,293 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$2.43
-5.1%
$2.97
$2.27
$26.05
$41.61M2.77148,955 shs212,151 shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.00
$1.22
$8.45
$45.46M1.5329,344 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
+7.08%+11.27%+30.46%+4.13%-16.54%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
+6.73%-11.73%-3.77%+29.97%-4.55%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-0.78%-4.83%-10.18%-54.12%-87.61%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%+4,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.14
-5.7%
$2.07
$1.63
$3.26
$13.17M0.8540,117 shs51,377 shs
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$1.10
-2.7%
$1.29
$0.64
$2.92
$46.01M-0.7529,800 shs162,293 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$2.43
-5.1%
$2.97
$2.27
$26.05
$41.61M2.77148,955 shs212,151 shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.00
$1.22
$8.45
$45.46M1.5329,344 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
+7.08%+11.27%+30.46%+4.13%-16.54%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
+6.73%-11.73%-3.77%+29.97%-4.55%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-0.78%-4.83%-10.18%-54.12%-87.61%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%+4,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCardia, Inc. stock logo
BCDA
BioCardia
3.50
Strong Buy$25.001,068.22% Upside
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
3.00
Buy$3.00172.73% Upside
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.60
Moderate Buy$28.751,083.13% Upside
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BCDA, BRNS, JSPR, and NBRV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$29.00 ➝ $25.00
7/8/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformSector Perform$5.00
7/8/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$70.00 ➝ $12.00
7/8/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$50.00 ➝ $20.00
7/8/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformMarket Perform
7/7/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$40.00 ➝ $20.00
7/7/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$64.00 ➝ $20.00
7/7/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweightNeutral
7/7/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformMarket Perform
(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCardia, Inc. stock logo
BCDA
BioCardia
$60K206.87N/AN/A$0.18 per share11.89
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$14.97M2.99N/AN/A$3.23 per share0.34
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/A$4.11 per shareN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCardia, Inc. stock logo
BCDA
BioCardia
-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%11/11/2025 (Estimated)
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$71.27M-$6.01N/AN/AN/AN/A-172.28%-128.34%11/6/2025 (Estimated)
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A

Latest BCDA, BRNS, JSPR, and NBRV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$1.20-$1.74-$0.54-$1.74N/AN/A
8/11/2025Q2 2025
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.50-$0.40+$0.10-$0.40N/AN/A
8/7/2025Q2 2025
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$0.29-$0.52-$0.23-$0.52N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
0.33
0.33
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/A
7.89
7.89
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/A
2.10
2.10
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52

Institutional Ownership

CompanyInstitutional Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
25.20%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
79.85%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.27%

Insider Ownership

CompanyInsider Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.00%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10.70%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
4.60%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
1.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
405.80 million4.64 millionOptionable
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10740.72 million36.36 millionN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2016.25 million15.51 millionOptionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
7032.02 million31.49 millionNot Optionable

Recent News About These Companies

Nabriva Therapeutics plc (NBRVF)
Meitheal gains rights to Contempo
Meitheal gains rights to CONTEPO from Nabriva in North America
Nabriva Therapeutics PLC NBRVF
Nabriva Therapeutics files patent for a dosing regimen for fosfomycin treatment
NBRV - Nabriva Therapeutics plc
NBRV Nabriva Therapeutics plc
Nabriva Therapeutics Provides Corporate Update
Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis
Nabriva's stock is up after sharing antibiotic news

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCardia stock logo

BioCardia NASDAQ:BCDA

$2.14 -0.13 (-5.73%)
Closing price 03:59 PM Eastern
Extended Trading
$2.14 0.00 (0.00%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$1.10 -0.03 (-2.65%)
Closing price 03:50 PM Eastern
Extended Trading
$1.10 0.00 (-0.36%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPR

$2.43 -0.13 (-5.08%)
Closing price 04:00 PM Eastern
Extended Trading
$2.47 +0.04 (+1.81%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Nabriva Therapeutics stock logo

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.